Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
23.22
-0.46 (-1.94%)
May 29, 2026, 4:00 PM EDT - Market closed
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $177.38M in the quarter ending March 31, 2026, with 5.00% growth. This brings the company's revenue in the last twelve months to $734.86M, up 4.57% year-over-year. In the year 2025, Pacira BioSciences had annual revenue of $726.41M with 3.63% growth.
Revenue (ttm)
$734.86M
Revenue Growth
+4.57%
P/S Ratio
1.24
Revenue / Employee
$886,446
Employees
829
Market Cap
913.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 726.41M | 25.45M | 3.63% |
| Dec 31, 2024 | 700.97M | 25.99M | 3.85% |
| Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
| Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
| Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
| Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
| Dec 31, 2019 | 421.03M | 83.75M | 24.83% |
| Dec 31, 2018 | 337.28M | 50.65M | 17.67% |
| Dec 31, 2017 | 286.63M | 10.26M | 3.71% |
| Dec 31, 2016 | 276.37M | 27.37M | 10.99% |
| Dec 31, 2015 | 249.00M | 51.33M | 25.97% |
| Dec 31, 2014 | 197.67M | 112.12M | 131.05% |
| Dec 31, 2013 | 85.55M | 46.47M | 118.89% |
| Dec 31, 2012 | 39.08M | 23.40M | 149.12% |
| Dec 31, 2011 | 15.69M | 1.13M | 7.74% |
| Dec 31, 2010 | 14.56M | -444.00K | -2.96% |
| Dec 31, 2009 | 15.01M | 1.08M | 7.76% |
| Dec 31, 2008 | 13.93M | 5.58M | 66.95% |
| Dec 31, 2007 | 8.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Phibro Animal Health | 1.50B |
| Evotec SE | 859.03M |
| Collegium Pharmaceutical | 796.33M |
| Amphastar Pharmaceuticals | 720.53M |
| Alvotech | 562.04M |
| Esperion Therapeutics | 418.24M |
| Xeris Biopharma Holdings | 314.85M |
| Harrow | 268.68M |
PCRX News
- 1 day ago - Glass Lewis recommends shareholders vote for Pacira director nominees - TheFly
- 1 day ago - Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira's Director Nominees - GlobeNewsWire
- 1 day ago - DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION - PRNewsWire
- 1 day ago - Pacira BioSciences Proxy statement: Proxy filing - Filings
- 2 days ago - Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified Nominees - GlobeNewsWire
- 2 days ago - Pacira study shows Exparel reduces opioid use and costs - TheFly
- 2 days ago - Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty - GlobeNewsWire
- 2 days ago - Pacira BioSciences Proxy statement: Proxy filing - Filings